Location of Repository

The role of external resource acquisition in firm strategy: the case of biopharmaceuticals

By Sotiris Konstantinos Rompas

Abstract

This dissertation investigates the role which the acquisition of external resources plays in firm strategy. External Resource Acquisition (ERA) is a core strategic action for firm survival, especially when firms are faced with high munificence and uncertainty in regards to their resource environment. Primarily driven by the theoretical premises of the Resource Based View (RBV) of the firm (Barney, 1991; Wernerfelt, 1984), scholars have conceptualized ERA as predominantly a resource-driven action. Under this view, firms engage in ERA to alleviate their resource constraints (Combs & Ketchen, 1999), access complementary resources (e.g., Rothaermel, 2001b), and further enhance their knowledge base (e.g., Ahuja & Katila, 2001).\ud These contributions significantly advance understanding on various dimensions of ERA, but they treat the competitive environment of the firm as an exogenous factor. While there is a good theoretical rationale of the exclusion of the competitive environment in terms of the explanatory power of the RBV and its theoretical limits (Peteraf & Barney, 2003), the treatment of ERA as solely a resource-driven action, I argue, significantly fails to provide a holistic assessment on the strategic implications of ERA. I address this gap by a) developing a conceptual framework of ERA that takes into account both the firm’s idiosyncratic attributes and its competitive environment, and b) providing an extensive empirical analysis on the patterns of ERA activity among competing firms. Departing from this resource-driven view of ERA, I argue that ERA can be also seen as a competitor-driven action. I propose that firms engage in ERA to also respond to their competitive environment and more specifically to their competitors’ ERA-related actions. To build the competitive side of my argument, I draw upon the competitive dynamics literature and theories of interorganizational imitation. Taking these two views together, I argue that ERA can be seen as a strategic action that leads to a broader set of strategic choices.\ud Drawing from an extensive sample of 4,729 ERA actions among the top 50 biopharmaceutical firms between 1987 and 2006, my empirical analysis provides overall support for both the resource- and competitor- driven views of ERA.\ud This dissertation makes at least three contributions to the field of strategy. First, it illustrates that firm strategy, at least in the context of ERA, can be better explained when both firm- and competitor- specific explanations of firm action are taken into account. This particularly important for scholars who view firms from a RBV point of view, and tend to exclude the competitive environment of the firm from their conceptual development and analysis. Second, to better understand complex strategic actions, such as ERA, scholars must adopt a broader theoretical perspective of strategic choice. The empirical support of ERA as both resource- and competitor- driven, illustrates that firm strategy cannot be sufficiently explained by one theoretical view. Third, my empirical analysis provides support for the temporal dimension of strategy, when firms are faced with changing technological paradigms. In the case of the biotechnology paradigm, for example, the extent which firm- and competitor- specific factors explain patterns of ERA changes over time

Topics: HD
OAI identifier: oai:wrap.warwick.ac.uk:2239

Suggested articles

Preview

Citations

  1. (1991). A Historical Comparison of Resource-Based Theory and Five Schools of Thought Within Industrial Organization Economics: Do We Have a New Theory of the Firm?
  2. (2000). A Resource-Based Theory of Strategic Alliances.
  3. (1984). A resource-based view of the firm.
  4. (2007). A Review of Approaches to Empirical Research on the Resource-Based View of the Firm.
  5. (1990). Absorptive capacity: a new perspective on learning and innovation.
  6. (2003). Alliance From: a Test of the Contractual and Competence Perspectives.
  7. (2002). Alliance Management as a Source of Competitive Advantage.
  8. (2007). Alliance networks and firm performance: The impact of repeated partnerships.
  9. (1998). Alliances and networks.
  10. (1999). Ambiguity and the process of knowledge transfer in strategic alliances.
  11. (2006). An introduction to modern econometrics using Stata: Stata Corp.
  12. (2004). Applied logistic regression:
  13. (2002). Appropriability Hazards and Governance in Strategic Alliances: A Transaction Cost Approach.
  14. (2002). Asset Accumulation, Interdependence and Technological Change: Evidence from Pharmaceutical Drug Discovery.
  15. (1989). Asset Stock Accumulation and Sustainability of Competitive Advantage.
  16. (2004). Asymmetric Performance: the Market Share Impact of Scale and Link Alliances in the Global Auto Industry.
  17. (2006). Balancing Exploration and Exploitation in Alliance Formation.
  18. (2006). Balancing vertical integration and strategic outsourcing: effects on product portfolio, product success, and firm performance.
  19. (1998). Bandwagon pressures and interfirm alliances in the global pharmaceutical industry.
  20. (2003). Benefits of co-operation on innovative performance: evidence from integrated circuits and biotechnology firms in the UK and Taiwan.
  21. (2001). Beyond Local Search: Boundary-Spanning, Exploration, and Impact in the Optical Disc Industry.
  22. (2003). Co-operative R&D: why and with whom?: An integrated framework of analysis.
  23. (2005). Collaboration and innovation: a review of the effects of mergers, acquisitions and alliances on innovation.
  24. (2000). Collaboration Networks, Structural Holes, and Innovation: A Longitudinal Study.
  25. (2007). Competing in the looking-glass market: imitation, resources, and crowding.
  26. (1972). Competition in the major home appliance industry,
  27. (1992). Competitive advantages from in-house scientific research:
  28. (1994). Competitive Attack, Retaliation and Performance: An Expectancy-Valence Framework.
  29. (1996). Competitive dynamics of interfirm rivalry.
  30. (2008). Competitive intensity and collaboration: impact on firm growth across technological environments.
  31. (2008). COMPETITORS' RESOURCE-ORIENTED STRATEGIES: ACTING ON COMPETITORS'
  32. (1990). Complementarity and external linkages: the strategies of the large firms in biotechnology.
  33. (2000). Complementarity, status similarity and social capital as drivers of alliance formation.
  34. (2001). Complementary assets, strategic alliances, and the incumbents advantage: an empirical study of industry and firm effects in the biopharmaceutical industry.
  35. (2004). Computing interaction effects and standard errors in logit and probit models.
  36. (2005). Conceptualizing and measuring capabilities: methodology and empirical application.
  37. (1992). Core Capabilities and Core Rigidities: a Paradox in Managing New Product Development.
  38. (2001). Determinants and performance impacts of external technology acquisition.
  39. (2000). Do Firms Learn to Create Value: the Case of Alliances.
  40. (1996). Does Isomorphism Legitimate?
  41. (2000). Don't Go it Alone: Alliance Network Composition and Startups' Performance in Canadian Biotechnology.
  42. (2006). Drug discovery in jeopardy.
  43. (1999). Dynamics of dyadic competitive interaction.
  44. (1995). Econometric analysis of panel data.
  45. (1984). Econometric Models for Count Data with an Application to the Patents-R
  46. (2005). Embedded Ties and the Acquisition of Competitive Capabilities.
  47. (2007). Empirical research on the resource-based view of the firm: an assessment and suggestions for future research.
  48. (2006). Encouraging Best Practice in Quantitative Management Research: An Incomplete List of Opportunities*.
  49. (2008). Entry into insular domains: a longitudinal study of knowledge structuration and innovation in biotechnology firms.
  50. (2000). Equilibrium vs. evolution in the resource-based perspective. In
  51. (1999). Explaining interfirm cooperation and performance: toward a reconciliation of predictions from the resourcebased view and organizational economics.
  52. (2004). Exploration and exploitation alliances in biotechnology: a system of new product development.
  53. (2006). Exploration and exploitation in innovation systems: The case of pharmaceutical biotechnology.
  54. (1995). External partnering as a response to innovation barriers and global competition in biotechnology.
  55. (2005). External Sources of Knowledge, Governance Mode, and R&D Performance.
  56. (1991). Firm Resources and Sustained Competitive Advantage.
  57. (2007). Firm, strategic group, and industry influences on performance.
  58. (2004). Firms' Technological Resources and the Performance Effects of Diversification: a Longitudinal Study.
  59. (1998). First-mover (dis)advantages: retrospective and link with the resource-based view. Strategic Management Journal,
  60. (1988). First-mover advantages.
  61. (1993). Follow the Leader: Mimetic Isomorphism and Entry Into New Markets.
  62. (2002). Followers' entry timing: evidence from the Spanish banking sector after deregulation.
  63. (1977). From Entry Barriers to Mobility Barriers: Conjectural Decisions and Contrived Deterrence to New Competition.
  64. (1994). Fundamental Issues in Strategy. In
  65. (1996). Generic Knowledge Strategies in the U.S. Pharmaceutical Industry.
  66. (1997). Getting to Know You: a Theory of Strategic Group Identity.
  67. (1991). Global Strategic Linkages and Industry Structure.
  68. (2005). Growth dynamics: the bidirectional relationship between interfirm collaboration and business sales in entrant and incumbent alliances.
  69. (2003). Guest Editors' Introduction to the Special Issue: Why is there a Resource-Based View? Toward a Theory of Competitive Heterogeneity.
  70. (1996). Hypercompetition in a Multimarket Environment: The Role of Strategic Similarity and Multimarket Contact in Competitive De-escalation.
  71. (1994). Hypercompetition: managing the dynamics of strategic maneuvering: The Free Press Toronto:
  72. (2006). In search of complementarity in innovation strategy: internal R&D and external knowledge acquisition.
  73. (2005). In-licensing in the pharmaceutical industry.
  74. (2000). Incumbency and R&D incentives: licensing the gale of creative destruction.
  75. (2001). Incumbent's advantage through exploiting complementary assets via interfirm cooperation.
  76. (2003). Innovation and Strategic Divergence: An Empirical Study of the U.S. Pharmaceutical Industry from
  77. (1993). Institutional and Competitive Bandwagons: Using Mathematical Modeling as a Tool to Explore Innovation Diffusion.
  78. (2006). Inter-firm R&D partnering in pharmaceutical biotechnology since 1975: Trends, patterns, and networks.
  79. (2002). Inter-firm R&D partnerships: an overview of major trends and patterns since
  80. (1997). Internal R&D expenditures and external technology sourcing.
  81. (2000). Interorganizational Alliances and the Performance of Firms: a Study of Growth and Innovation rates in high-technology industry.
  82. (2005). Interorganizational Collaboration and Innovation: Toward a Portfolio Approach.
  83. (1996). Interorganizational collaboration and the locus of innovation: networks of learning in biotechnology.
  84. (1993). Interorganizational imitation: The impact of interlocks on corporate acquisition activity. Administrative Science Quarterly:
  85. (2003). Knowledge Dynamics: Biotechnology's Incursion into the Pharmaceutical Industry.
  86. (2002). Licensing agreements in the pharmaceutical industry.
  87. (2004). Licensing as a commercialisation strategy for new technology-based firms.
  88. (2002). Local versus global mimetism: the dynamics of alliance formation in the automobile industry.
  89. (2007). Location Strategies and Knowledge Spillovers.
  90. (1999). Make and buy in innovation strategies: evidence from Belgian manufacturing firms.
  91. (1975). Markets and Hierarchies: Analysis and Antitrust Applications.
  92. (1999). Matching method to paradigm in strategy research: Limitations of cross-sectional analysis and some..
  93. (1994). Measuring Competence? Exploring Firm Effects in Pharmaceutical Research.
  94. (1990). Mergers and Acquisitions and Managerial Commitment to Innovation in M-Form Firms.
  95. (2008). Mimetic entry and bandwagon effect: the rise and decline of international equity joint venture in China.
  96. (2004). Modeling limited dependent variables: Methods and guidelines for researchers in strategic management.
  97. (1997). Modes of Interorganizational Imitation: The Effects of Outcome Salience and Uncertainty.
  98. (2000). Multimarket Contact and Resource Dissimilarity: A Competitive Dynamics Perspective.
  99. (2006). Multipoint competition, strategic similarity and entry into geographic markets.
  100. (2005). Network Dynamics and Field Evolution: The Growth of Interorganizational Collaboration in the Life Sciences.
  101. (1999). Network location and learning: the influence of network resources and firm capabilities on alliance formation.
  102. (1998). Network Positions and Propensities to Collaborate: An Investigation of Strategic Alliance Formation in a High-Technology Industry.
  103. (2008). Old technology meets new technology: complementarities, similarities, and alliance formation.
  104. (2006). Open for innovation: the role of openness in explaining innovation performance among U.K. manufacturing firms.
  105. (2004). Open Innovation: The New Imperative for Creating and Profiting from Technology: Henry W. Chesbrough,
  106. (2005). Organizational Integration of Acquired Biotechnology Companies into Pharmaceutical Companies: The Need for a Hybrid Approach.
  107. (2006). Patent Protection, Complementary Assets, and Firms' Incentives for Technology Licensing.
  108. (2000). Path-dependent and path-breaking change: reconfiguring business resources following acquisitions in the U.S. medical sector,
  109. (1988). Performance Differences among Strategic Group Members.
  110. (2008). Performance effects of imitative entry.
  111. (1998). Pharmaceutical Firms and the Transition to Biotechnology: A Study in Strategic Innovation.
  112. (2004). Portfolios of interfirm agreements in technology-intensive markets: Consequences for innovation and profitability.
  113. (2007). Position, leverage and opportunity: a typology of strategic logics linking resources with competitive advantage. Managerial and Decision Economics:
  114. (2006). Positioning among organizations in a population: Moves between market segments and the evolution of industry structure.
  115. (2004). presented at the Academy of Management Proceedings.
  116. (2006). Product and process innovation in biopharmaceuticals: a new perspective on development.
  117. (2005). Productivity in pharmaceutical --biotechnology R&D: the role of experience and alliances.
  118. (1997). Regression models for categorical and limited dependent variables:
  119. (2006). Regression Models for Categorical Dependent Variables Using Stata:
  120. (2004). Research on Competitive Dynamics: Recent Accomplishments and Future Challenges.
  121. (2001). Resource complementarity in business combinations: Extending the logic to organizational alliances.
  122. (1998). Resource recombinations in the firm: knowledge structures and the potential for schumpeterian innovation.
  123. (1996). Resource-Based View of Strategic Alliance Formation: Strategic and Social Effects in Entrepreneurial Firms.
  124. (1999). Rethinking research methods for the resource-based perspective: Isolating sources of sustainable.
  125. (1993). Rivalry, Strategic Groups and Firm Profitability.
  126. (1996). Scale, scope, and spillovers: The determinants of research productivity in drug discovery.
  127. (2003). Scanning dynamic competitive landscapes: a market-based and resource-based framework.
  128. (2002). Something Old, Something New: a Longitudinal Study of Search Behavior and New Product Introduction.
  129. (1994). Sources and Consequences of Competitive Inertia:
  130. (2003). Sources and financial consequences of radical innovation: insights from pharmaceuticals.
  131. (1978). Specification tests in econometrics.
  132. (2003). Startup size and the mechanisms of external learning: increasing opportunity and decreasing ability?
  133. (2005). Strategic alliances and models of collaboration.
  134. (1993). Strategic Assets and Organizational Rent.
  135. (2001). Strategic Factor Market Intelligence:An Application of Information Economics to Strategy Formulation and Competitor Intelligence.
  136. (1995). Strategic Groups as Reference Groups: Theory, Modeling and Empirical Examination of Industry and Competitive Strategy.
  137. (1993). Strategic Groups: A Cognitive Perspective.
  138. (1986). Strategic Groups: Theory, Research and Taxonomy.
  139. (2000). Strategic Management and the Philosophy of Science: The Case for a Constructivist Methodology.
  140. (2000). Strategic Networks.
  141. (2007). Strategies for managing a portfolio of alliances.
  142. (2003). Strategizing by firms in the presence of markets for resources.
  143. (2006). Strategy as Action: Competitive Dynamics and Competitive Advantage.
  144. (1996). Survival of Businesses using Collaborative Relationships to Commercialize Complex Goods.
  145. (2002). Sustained Competitive Advantage: Temporal Dynamics and the Incidence and Persistence of Superior Economic Performance.
  146. (2001). Technological acquisitions and the innovation performance of acquiring firms: a longitudinal study.
  147. (1998). Technological overlap and interfirm cooperation: implications for the resource-based view of the firm.
  148. (2003). Technology Sourcing and Output of Established Firms in a Regime of Encompassing Technological Change.
  149. (1998). The Co-evolution of Strategic Alliances.
  150. (2006). The Competitive Advantage of Interconnected Firms: an Extension of the Resource-Based View.
  151. (2006). The convergence of biotechnology and nanotechnology: Why here, why now?
  152. (1993). The Cornerstones of Competitive Advantage: A ResourceBased View.
  153. (1997). The Dynamics of Competitive Intensity.
  154. (2003). The Dynamics of Innovative Activity and Competitive Advantage: The Case of Australian Retail Banking,1981 to
  155. (2005). The effect of alliance network diversity on multinational enterprise performance.
  156. (2005). The Effect of General and PartnerSpecific Alliance Experience on Joint R&D Project Performance.
  157. (1994). The Effect of Strategic Technology Alliances on Company Performance.
  158. (2007). The Entrepreneurial Theory of the Firm and the Theory of the Entrepreneurial Firm*.
  159. (2007). The Entrepreneurial Theory of the Firm.
  160. (1996). The Evolution of Cooperation in Strategic Alliances: Initial Conditions or Learning Processes?
  161. (2002). The evolution of organizational niches.
  162. (2005). The impact of acquisitions on innovation: poison pill, placebo, or tonic?
  163. (2000). The influence of corporate acquisitions on the behavior of key inventors.
  164. (1983). The iron cage revisited: Institutional isomorphism and collective rationality in organizational fields. American sociological review:
  165. (2008). The many moods of interorganizational imitation: A critical review.
  166. (1993). The myopia of learning.
  167. (2002). The new math for drug licensing. McKinsey Quarterly(4): 9.
  168. (2006). The ongoing process of building a theory of disruption.
  169. (2003). The optimum time for drug licensing.
  170. (2003). The price of innovation: new estimates of drug development costs.
  171. (1995). The problem of unobservables in strategic management research.
  172. (1990). The R&D Boundaries of the Firm: An Empirical Analysis.
  173. (2006). The Reification of Absorptive Capacity: a Critical Review and Rejuvenation of the Construct.
  174. (1998). The Relational View: Cooperative Strategy and Sources of Interorganizational Competitive Advantage.
  175. (2003). The resource-based tangle: towards a sustainable explanation of competitive advantage.
  176. (1992). The Resource-Based View Within the Conversation of Strategic Management.
  177. (2004). The scope and governance
  178. (2000). The Structure of Licensing Contracts.
  179. (1979). The Structure within Industries and Companies Performance.
  180. (2008). The Timing of International Expansion: Information, Rivalry and Imitation Among Japanese Firms,
  181. (2007). The use of Knowledge for Technological Innovation within Diversified Firms.
  182. (2007). The use of logit and probit models in strategic management research: Critical issues.
  183. (2006). Thirty Years of Mergers and Acquisitions Research: Recent Advances and Future Opportunities.
  184. (1999). To be different, or to be the same? It?s a question (and theory) of strategic balance.
  185. (2006). To Conform or To Perform? Mimetic Behaviour, Legitimacy-Based Groups and Performance Consequences.
  186. (1996). Toward a Knowledge-Based Theory of the Firm.
  187. (2001). Toward a Synthesis of the Resource-Based and DynamicCapability Views of Rent Creation.
  188. (2007). Towards a Dynamic Resource-based View: Insights from Austrian Capital and Entrepreneurship Theory.
  189. (2009). Understanding the alliance data.
  190. (1993). Understanding the Rationale of Strategic Technology Partnering: Interorganizational Modes of Cooperation and Sectoral Differences.
  191. (2001). Unlocking the value in big pharma.
  192. (2003). Unraveling the resource-based tangle.
  193. Value drivers in licensing deals.
  194. (2004). Where do resources come from? the role of idiosyncratic situations.
  195. (1989). Whether and When? Probability and Timing of Incumbents' Entry into Emerging Industrial Subfields.
  196. (2006). Who Do Firms Imitate? A Multilevel Approach to Examining Sources of Imitation in the Choice of Mergers and Acquisitions.
  197. (2006). Why do Firms Imitate each Other?
  198. (2006). Winning R&D productivity strategies: Exploiting innovation, licensing and outsourcing opportunities.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.